Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral

Crispr Therapeutics Coverage Assumed by Guggenheim at Neutral

Dow JonesJun 28 08:06 ET

Guggenheim Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating

Guggenheim analyst Debjit Chattopadhyay initiates coverage on $CRISPR Therapeutics(CRSP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 45.2% and a total average

Moomoo NewsJun 28 06:31 ET · Ratings

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued."

Yahoo FinanceJun 27 08:00 ET

CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing

Yahoo FinanceJun 26 18:00 ET

Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 Mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapyFollow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28

BenzingaJun 25 15:32 ET

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Yahoo FinanceJun 20 18:00 ET